Skip to main content
. 2022 Feb 21;2022:9557859. doi: 10.1155/2022/9557859

Figure 3.

Figure 3

hsa-miR-582-5p negatively regulates Siglec-15 level and its induced immunosuppression. (a) hsa-miR-582-5p expression in HCC patients and normal person from GEO analysis (GPL8179). (b) hsa-miR-582-5p in different HCC cell lines (HepG2, QGY-7701, Bel-7407, SK-Hep-1, Hep3B, and HUH7), human normal hepatic cell line LO-2, and primary human hepatocytes HH. (c, f) TUG1 expression, Siglec-15 mRNA expression, and protein expression in HUH7 and Hep3B cells treated with hsa-miR-582-5p mimics or inhibitor. hsa-miR-582-5p expression in (g) HUH7 and (h) Hep3B cells treated TUG1 overexpression or knockdown. (i, j) hsa-miR-582-5p expression, (i, j) Siglec-15 mRNA, and (k, l) protein expression in HUH7-miRKO and Hep3B-miRKO cells treated TUG1 overexpression or knockdown. (m, n) Relative luciferase activity of Jurkat-RGA in HUH7 and Hep3B cells treated with hsa-miR-582-5p mimics or inhibitor. (o, p) T cell-induced cytotoxicity cocultured with HUH7 and Hep3B cells treated with hsa-miR-582-5p mimics or inhibitor. (q, r) IFN-γ and (s, t) IL-2 secreted by T cells from (o, p). The data are presented as the means ± SD, n = 3 replicates in (b–t). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005. S15: Siglec-15.